NCT02971501 2026-03-17
Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
177 trialsNCT03074513 2026-03-11
Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT05263947 2026-02-24
Bevacizumab Combined With Double Doses of Icotinib in Advanced NSCLC Patients With EGFR L858R Mutation
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Completed
NCT03896074 2026-02-09
BEAT
Fondazione Ricerca Traslazionale
Phase 2 Active not recruiting
NCT03133546 2026-02-06
BOOSTER
ETOP IBCSG Partners Foundation
Phase 2 Completed
NCT07288034 2025-12-17
Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial
City of Hope Medical Center
Phase 2 Not yet recruiting
NCT07244926 2025-11-24
Sac-TMT Plus Bevacizumab as Second-Line Treatment for Advanced Non-Squamous Non-Small Cell Lung Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT05781308 2025-11-18
ADAPTABLE
Intergroupe Francophone de Cancerologie Thoracique
Phase 2 Active not recruiting
NCT05588388 2025-11-17
BELIEVE
Cedars-Sinai Medical Center
Phase 2 Recruiting
NCT00334815 2025-08-24
Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT07134413 2025-08-21
QL1706/Bevacizumab ± Chemotherapy in Post-ICI Non-Squamous NSCLC
Guangdong Association of Clinical Trials
Phase 2 Not yet recruiting
NCT02681549 2025-08-07
Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer (NSCLC)
Yale University
Phase 2 Completed
NCT07083375 2025-07-24
QL1706
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Not yet recruiting
NCT07001618 2025-07-23
IMMUNOLIFE2
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Not yet recruiting
NCT06953843 2025-07-14
Study on the Optimal Combination Pattern of the Combined Treatment of Radiotherapy and Immunotherapy for the Abscopal Effect in Non-Small Cell Lung Cancer (NSCLC) With Multiple Metastases
Xinqiao Hospital of Chongqing
Phase 2 Recruiting
NCT06276283 2025-06-19
DZD9008 In Combination With Bevacizumab in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutation (WU-KONG29)
Dizal Pharmaceuticals
Phase 2 Recruiting
NCT07014215 2025-06-10
PD-1 Combined With Bevacizumab and PCSK-9 Inhibitor in Patients With Advanced NSCLC Who Have Progressed After Anti- PD- 1/L1 Therapy
Anhui Provincial Cancer Hospital
Phase 2 Not yet recruiting
NCT04042558 2025-05-31
GFPC 06-2018
Centre Francois Baclesse
Phase 2 Completed
NCT06401824 2025-05-06
Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases
Maastricht University Medical Center
Phase 2 Recruiting
NCT04512430 2025-04-02
Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients
Fundación GECP
Phase 2 Terminated
NCT04997382 2025-02-25
CLASSIC5
Hunan Province Tumor Hospital
Phase 2 Completed
NCT06749860 2024-12-27
Disitamab Vedotin in Combination with Tislelizumab and Bevacizumab in a Phase II Clinical Study of Locally Advanced or Metastatic Non-small Cell Lung Cancer with HER2 Mutation/amplification/expression
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2 Recruiting
NCT06728865 2024-12-11
Better Brain
Sun Yat-sen University
Phase 2 Recruiting
NCT03872661 2024-12-06
NIBCUN
Sun Yat-sen University
Phase 2 Recruiting
NCT06683703 2024-11-12
Utidelone Injection Combined with Bevacizumab Injection for Non-small Cell Lung Cancer Patients with Brain Metastases
Beijing Biostar Pharmaceuticals Co., Ltd.
Phase 2 Not yet recruiting
NCT05468242 2024-10-30
Study of Tislelizumab for Locally Advanced Non-Small Cell Lung Cancer Following Neoadjuvant Chemotherapy Plus Tislelizumab ± Bevacizumab and Definitive Concurrent Chemoradiation Therapy
Sun Yat-sen University
Phase 2 Recruiting
NCT00309998 2024-10-29
Vinorelbine and Bevacizumab in Treating Older Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
University of Rochester
Phase 2 Completed
NCT06537297 2024-09-20
Intrathecal Pemetrexed Combined With High-dose Furmonertinib and Beva for EGFR-m NSCLC With Leptomeningeal Metastases
Hunan Province Tumor Hospital
Phase 2 Not yet recruiting
NCT05491811 2024-09-19
EAGLE
Sun Yat-sen University
Phase 2 Active not recruiting
NCT00998166 2024-07-30
A Study of Cisplatin + Pemetrexed + Avastin as First-Line Therapy
Columbia University
Phase 2 Terminated
NCT06492421 2024-07-09
Neoadjuvant Intra-tumor Double Immunotherapy for Lung Cancer.
Second Affiliated Hospital of Guangzhou Medical University
Phase 2 Recruiting
NCT04730999 2024-07-05
CeLEBrATE
Gruppo Oncologico Italiano di Ricerca Clinica
Phase 2 Completed
NCT06483347 2024-07-03
Checkpoint Inhibitor Combinations Therapy as First Line for Inoperable Lung Cancer Via IT
Second Affiliated Hospital of Guangzhou Medical University
Phase 2 Recruiting
NCT05284539 2024-06-07
Awesome
Hunan Province Tumor Hospital
Phase 2 Recruiting
NCT04322578 2024-06-04
CONFIRM
Hunan Province Tumor Hospital
Phase 2 Recruiting
NCT05266846 2024-05-30
BEYOND
Hunan Province Tumor Hospital
Phase 2 Recruiting
NCT04426825 2024-05-21
A Study of Atezolizumab in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer
Hoffmann-La Roche
Phase 2 Completed
NCT04147351 2024-04-16
A Phase II Study of Atezolizumab in Combination With Bevacizumab, Carboplatin or Cisplatin, and Pemetrexed for EGFR-mutant Metastatic Non-small Cell Lung Cancer Patients After Failure of EGFR Tyrosine Kinase Inhibitors.
National Taiwan University Hospital
Phase 2 Active not recruiting
NCT04310943 2024-03-06
Efficacy and Safety of Tislelizumab Combined With Bevacizumab and Albumin Paclitaxel in Lung Adenocarcinoma
Guangzhou Institute of Respiratory Disease
Phase 2 Completed
NCT04238169 2024-02-28
Clinical Trial Assessing the Efficacy of Abscopal Effect Induced by SBRT and Immunotherapy in Advanced NSCLC
Xinqiao Hospital of Chongqing
Phase 2 Completed
NCT06229340 2024-01-29
NТО-RAS
N.N. Petrov National Medical Research Center of Oncology
Phase 2 Recruiting
NCT05296278 2024-01-10
Efficacy and Biomarker Explanation of IBI-323 + Bevacizumab Plus Platinum Based Chemotherapy on ALK-Rearranged NSCLC
Hunan Province Tumor Hospital
Phase 2 Recruiting
NCT06182800 2023-12-27
Adebrelimab Combined With Bevacizumab and Docetaxel for Advanced Non-Squamous Non-small Cell Lung Cancer After Progression on First-line Immunotherapy
The First Affiliated Hospital of Xinxiang Medical College
Phase 2 Unknown
NCT04099836 2023-12-26
Atezolizumab and Bevacizumab in EGFR Mutant NSCLC in Patients With Progressive Disease After Receiving Osimertinib
Duke University
Phase 2 Terminated
NCT04345146 2023-08-28
Bevacizumab Combined With Fractionated Stereotactic Radiotherapy for 1 to 10 Brain Metastases From NSCLC
Sun Yat-sen University
Phase 2 Completed
NCT00828009 2023-07-07
BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT04974879 2023-03-29
Osimertinib Combined With Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions Metastatic Non-Small Cell Lung Cancer
Qingdao Central Hospital
Phase 2 Unknown
NCT03654833 2023-03-14
MiST
University of Leicester
Phase 2 Unknown
NCT01705184 2023-03-13
BUCiL
Intergroupe Francophone de Cancerologie Thoracique
Phase 2 Completed
NCT03904563 2023-03-06
Bevacizumab After Chemoradiotherapy For Locally Advanced Lung Adenocarcinoma
Sun Yat-sen University
Phase 2 Completed